GDRX
GoodRx Holdings, Inc.
GDRX has a slight edge over NVO overall on the model score.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
GDRX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
GDRX's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
GDRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 10x | $3.51 | — |
| Cheap | 35x | $1.38 | -61% |
| Fair | 65x | $2.60 | -26% |
| Current | 88x | $3.51 | — |
| Expensive | 213x | $8.51 | +142% |
Historical ranges are pointers, not guarantees.
GDRX's PE is in its fair range at 88x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over GDRX in the historical PE scenario, which offers more potential upside but is not a forecast.
GDRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
GDRX has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
GDRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.35 | +778% |
| Q2 2026 | $0.04 | -56% |
| Q1 2026 | $0.06 | -14% |
| Q4 2025 | $0.09 | +125% |
| Q3 2025 | $0.08 | +$0.11 |
| Q2 2025 | $0.09 | +$0.22 |
| Q1 2025 | $0.07 | +$0.08 |
| Q4 2024 | $0.04 | +$0.06 |
| Q3 2024 | -$0.03 | -200% |
GDRX's earnings per share have fallen from their peak: $0.04 over the past year, against $0.20 in early 2020.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over GDRX on earnings, with more consistent year-over-year improvement.
GDRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $200.4M | -1.3% |
| Q1 2026 | $194M | -4.4% |
| Q4 2025 | $194.8M | -1.9% |
| Q3 2025 | $196M | +0.4% |
| Q2 2025 | $203.1M | +1.2% |
| Q1 2025 | $203M | +2.6% |
| Q4 2024 | $198.6M | +1% |
| Q3 2024 | $195.3M | +8.5% |
GDRX's revenue grew through 2021 and has held roughly level since: $200M last quarter, down 1.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 12% | -1.4 points |
| Q1 2026 | 7.2% | -4.3 points |
| Q4 2025 | 12% | +2.5 points |
| Q3 2025 | 7.5% | -3 points |
| Q2 2025 | 13% | +3.3 points |
| Q1 2025 | 12% | +7.8 points |
| Q4 2024 | 9.2% | +19 points |
| Q3 2024 | 10% | +32 points |
GDRX's operating margin was 12% last quarter, down 1.4 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over GDRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over GDRX on profitability, with a higher operating margin.
GDRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $80.5M | +64% |
| Q1 2026 | $10.7M | +15% |
| Q4 2025 | $31.6M | -29% |
| Q3 2025 | $74.3M | -14% |
| Q2 2025 | $49.2M | +421% |
| Q1 2025 | $9.3M | -78% |
| Q4 2024 | $44.6M | +188% |
| Q3 2024 | $86.5M | +44% |
GDRX's free cash flow has been positive every quarter for six years: $197M over the past year, up 4% from the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
GDRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +6.6M shares |
| 1 year | -2.5% | -9.1M shares |
| 3 years | -16% | -66.3M shares |
| 5 years | -19% | -80.8M shares |
| Available history | -4% | -14.5M shares |
GDRX has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $2M |
| Q1 2026 | $12.6M |
| Q4 2025 | $9.4M |
| Q3 2025 | $61.1M |
| Q2 2025 | $46M |
| Q1 2025 | $99.9M |
| Q4 2024 | $188,000 |
| Q3 2024 | $5.4M |
GDRX spent $85M buying back its own shares over the past year, down 44% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
GDRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 0.3x | Very low |
| Q3 2024 | 0.6x | Very low |
GDRX's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over GDRX on leverage, with a lower net debt burden relative to earnings.
GDRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.4 | Neutral |
| Stochastic | 50.9 | Neutral |
GDRX's weekly RSI is 58 (neutral) and its Stochastic is 51 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
GDRX PE vs Healthcare Sector
| Metric | GDRX | Sector median | Relative |
|---|---|---|---|
| PE | 88x | 26x | 239% above |
| PE % | 63 | 33 | 30 pts above |
GDRX is trading at 88x earnings, a 239% premium to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over GDRX on valuation relative to its sector.
GDRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.43 | 2.3% above |
| 20 week MA | $3.36 | 4.5% above |
| 50 week MA | $2.84 | 24% above |
| 100 week MA | $3.56 | 1.4% below |
| 200 week MA | $4.98 | 30% below |
GDRX has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
GDRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $52.0 | $46.3 | -11% |
| 2021 | $46.3 | $33.6 | -28% |
| 2022 | $33.6 | $4.59 | -86% |
| 2023 | $4.59 | $6.70 | +46% |
| 2024 | $6.70 | $4.62 | -31% |
| 2025 | $4.62 | $2.75 | -40% |
| 2026 YTD | $2.75 | $3.51 | +28% |
GDRX has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.